Publication | Open Access

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

OncologyImmunologyBronchial NeoplasmImmune Checkpoint InhibitorImmunotherapeuticsMage-a3 Cancer ImmunotherapeuticAdjuvant TherapyCancer TreatmentImmunotherapyMedicineLung Cancer